You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Details for Patent: 6,630,155


✉ Email this page to a colleague

« Back to Dashboard


Title: Controlled release liquid delivery compositions with low initial drug burst
Abstract:The invention provides a controlled release polymeric composition which includes a base polymer or copolymer, an organic solvent, a polymeric controlled release additive, and a biologically active agent. The polymeric controlled release additive reduces the initial burst of biologically active agent released from the polymeric composition as it is solidifying to form the solid implant. The controlled release additive is preferably a poly(lactide-co-glycolide)/polyethylene glycol block copolymer.
Inventor(s): Chandrashekar; Bhagya L. (Fort Collins, CO), Zhou; Mingxing (Fort Collins, CO), Jarr; Eileen M. (Fort Collins, CO), Dunn; Richard L. (Fort Collins, CO)
Assignee: Atrix Laboratories, Inc. (Fort Collins, CO)
Filing Date:Aug 22, 2000
Application Number:09/643,289
Claims:1. A polymeric composition for forming a controlled release implant within a body, comprising: a biocompatible, biodegradable, thermoplastic base polymer that is insoluble in aqueous or body fluids; a biocompatible, organic solvent that is soluble in aqueous or body fluid; a poly(lactide-co-glycolide)/polyethylene glycol block copolymer; and a biologically active agent wherein the polymeric composition is capable of forming the controlled release implant by dissipation or dispersement of the organic solvent within the body.

2. The polymeric composition of claim 1, wherein the poly(lactide-co-glycolide)/polyethylene glycol block copolymer includes from about 50 mole % to about 90 mole % lactide monomers and about 50 mole % to about 10 mole % glycolide monomers.

3. The polymeric composition of claim 1, wherein the organic solvent is selected from the group consisting of substituted heterocyclic compounds, esters of carbonic acid and alkyl alcohols, alkyl esters of monocarboxylic acids, alkyl esters of dicarboxylic acids, alkyl esters of tricarboxylic acids, alkyl ketones, alcohols, dialkylamides, dimethylsulfoxide (DMSO), dimethylsulfone, tetrahydrofuran, lactones, cyclic alkyl amides, aromatic amides, mixtures and combinations thereof.

4. The polymeric composition of claim 3, wherein the poly(lactide-co-glycolide)/polyethylene glycol block copolymer has an inherent viscosity from about 0.50 dL/g to about 1.00 dL/g.

5. A polymeric composition for forming a controlled release implant within a body, comprising: a biocompatible, biodegradable, thermoplastic base polymer that is insoluble in aqueous or body fluids; a biocompatible, organic solvent that is soluble in aqueous or body fluid; a polymeric controlled release additive that is insoluble in aqueous or body fluids and is a block copolymer of a biocompatible, biodegradable, thermoplastic polymer and polyethylene glycol; and a biologically active agent; wherein the base polymer, controlled release additive and solvent form a solution and the polymeric composition is capable of forming the controlled release implant by dissipation or dispersement of the organic solvent within the body.

6. A polymeric composition for forming a controlled release implant within a body, comprising: a biocompatible, biodegradable, thermoplastic base polymer that is insoluble in aqueous or body fluids; a biocompatible, organic solvent that is soluble in aqueous or body fluid; a polymeric controlled release additive that insoluble in aqueous or body fluid and is a block copolymer of a biocompatible, biodegradable, thermoplastic polymer and polyethylene glycol; and lidocaine HCl wherein the base polymer, controlled release additive and solvent form a solution and the polymeric composition is capable of forming the controlled release implant by dissipation or dispersement of the organic solvent within the body.

7. A polymeric composition for forming a controlled release implant within a body, comprising: a biocompatible, biodegradable, thermoplastic base polymer that is insoluble in aqueous or body fluids; a biocompatible, organic solvent that is soluble in aqueous or body fluid; a polymeric controlled release additive that insoluble in aqueous or body fluid and is a block copolymer of a biocompatible, biodegradable, thermoplastic polymer and polyethylene glycol; and floxuridine wherein the base polymer, controlled release additive and solvent form a solution and the polymeric composition is capable of forming the controlled release implant by dissipation or dispersement of the organic solvent within the body.

8. A polymeric composition for forming a controlled release implant within a body, comprising: a biocompatible, biodegradable, thermoplastic base polymer that is insoluble in aqueous or body fluids; a biocompatible, organic solvent that is soluble in aqueous or body fluid; a polymeric controlled release additive that is insoluble in aqueous or body fluid and is a block copolymer of a biocompatible, biodegradable, thermoplastic polymer and polyethylene glycol; and leuprolide acetate wherein the base polymer, controlled release additive and solvent form a solution and the polymeric composition is capable of forming the controlled release implant by dissipation or dispersement of the organic solvent within the body.

9. A method of forming a controlled release implant in situ within a body, comprising: placing a polymeric composition into an implant site within the body, wherein the polymeric composition comprises a biocompatible, biodegradable, thermoplastic base polymer that is insoluble in aqueous or body fluids; a biocompatible, organic solvent that is soluble in aqueous or body fluid; a poly(lactide-co-glycolisde)/polyethylene glycol block copolymer; and a biologically active agent, wherein the polymeric composition is capable of forming the controlled release implant by dissipation or dispersement of the organic solvent within the body.

10. The method of claim 9, wherein the poly(lactide-co-glycolide)/polyethylene glycol block copolymer includes from about 50 mole % to about 90 mole % lactide monomers and about 50 mole % to about 10 mole % glycolide monomers.

11. The method of claim 9, wherein the poly(lactide-co-glycolide)/polyethylene glycol block copolymer has an inherent viscosity from about 0.50 dL/g to about 1.00 dL/g.

12. A method of forming a controlled release implant in situ within a body, comprising: placing a polymeric composition into an implant site within the body, wherein the polymeric composition comprises a biocompatible, biodegradable, thermoplastic base polymer that is insoluble in aqueous or body fluids; a biocompatible, organic solvent that is soluble in aqueous or body fluid; a poly(lactide-co-glycolisde)/polyethylene glycol block copolymer; and a biologically active agent selected from the group consisting of lidocaine base, lidocaine HCl, floxuridine, and leuprolide acetate, wherein the polymeric composition is capable of forming the controlled release implant by dissipation or dispersement of the organic solvent within the body.

13. A method of forming a controlled release implant in situ within a body, comprising: placing a polymeric composition into an implant site within the body, wherein the polymeric composition comprises a biocompatible, biodegradable, thermoplastic base polymer that is insoluble in aqueous or body fluids; a biocompatible, organic solvent that is soluble in aqueous or body fluid; a polymeric controlled release additive that is insoluble in aqueous or body fluids and is a block copolymer of a biocompatible, biodegradable, thermoplastic polymer and polyethylene glycol; and a biologically active agent, wherein the base polymer, controlled release additive and solvent form a solution and the polymeric composition is capable of forming the controlled release implant by dissipation or dispersement of the organic solvent within the body.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.